10 Best 52-Week High Stocks to Buy According to Analysts

Page 9 of 9

1. Ascendis Pharma A/S (NASDAQ:ASND)

52 Week Range: $111.09 – $183

Current Share Price as of June 11: $173.34

Stock Upside Potential as of June 11: 30.45% 

Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts. On June 9, BofA analyst Tazeen Ahmad reiterated a ‘Buy’ rating on the stock and raised the price target to $216 from $201.

The adjustment follows the company delivering positive interim results from the Phase 2 COACH trial. The trial sought to ascertain the effectiveness of a combination treatment QW TransCon CNP and QW TransCon HGH in children with Achondroplasia (ACH). Trial results indicated significant annualized growth velocity benefits with the combination treatment.

According to the analyst, the trial results are favorable and likely to strengthen the company’s prospects of capturing market share once the treatment enters the market. Following the positive trial results, Ascendis plans to release 52-week data from the COACH trial in the fourth quarter.

Likewise, the US Food and Drug Administration (FDA) has accepted the company’s New Drug Application for TransCon, its candidate drug for treating achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and commercializes new therapies for unmet medical needs, particularly in endocrinology and oncology. It leverages a proprietary TransCon technology platform to create innovative and potentially best-in-class therapies.

While we acknowledge the potential of ASND to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ASND and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9